However, macromolecules (such as iDAbs), that bind either LEDGF or HIV IN, would also have potential for therapeutic application in early HIV infections and implementation should be possible by coupling new genome editing methods with using new delivery methods24,25 to allow expression of iDAbs in CD4+ T cells. This evidence concerns the gene CD4 and HIV infectious disease.